Selection of Neoadjuvant Treatment Arms in Trials of Patients With Squamous Cell Cancer of the Esophagus

Affiliations

¹ Department of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri.
² Division of Oncology, Department of Medicine, Washington University Medical School, St Louis, Missouri.

Comment

Nikolaos A Trikalinos et al. JAMA Surg. 2022.

. 2022 Jan 1;157(1):83-84.

doi: 10.1001/jamasurg.2021.4532.

¹ Department of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri.
² Division of Oncology, Department of Medicine, Washington University Medical School, St Louis, Missouri.

No abstract available

Comment in

Selection of Neoadjuvant Treatment Arms in Trials of Patients With Squamous Cell Cancer of the Esophagus-Reply.
Wang H, Tan L. Wang H, et al. JAMA Surg. 2022 Jan 1;157(1):84-85. doi: 10.1001/jamasurg.2021.4533. JAMA Surg. 2022. PMID: 34550313 No abstract available.

Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
Wang H, Tang H, Fang Y, Tan L, Yin J, Shen Y, Zeng Z, Zhu J, Hou Y, Du M, Jiao J, Jiang H, Gong L, Li Z, Liu J, Xie D, Li W, Lian C, Zhao Q, Chen C, Zheng B, Liao Y, Li K, Li H, Wu H, Dai L, Chen KN. Wang H, et al. JAMA Surg. 2021 May 1;156(5):444-451. doi: 10.1001/jamasurg.2021.0133. JAMA Surg. 2021. PMID: 33729467 Free PMC article. Clinical Trial.